Dr. Shannon Trotter, a dermatologist specializing in skin cancer in Columbus, Ohio, shares how DecisionDx-Melanoma offers personalized care for melanoma patients. Traditional staging places patients in broad risk categories, but DecisionDx-Melanoma takes it further, providing individualized insights into each patient’s unique risk of recurrence, metastasis, or positive sentinel node involvement. Dr. Trotter explains the simple, behind-the-scenes testing process, and emphasizes how these personalized results empower patients to make informed treatment and follow-up decisions. With advancements in gene expression profiling and new therapies, the future of melanoma treatment is more promising than ever, offering high-risk patients better options for improved outcomes.

свернуть